LOXAPINE inhalation powder (AdasuveĀ®)

Clinical Indication

Rapid control of mild-moderate agitation in schizophrenia or bipolar disorder

Comments

Not yet reviewed

Date of classification

September 2016

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.